NCT06079346View on ClinicalTrials.gov

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

OT-101

OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene

DRUG

mFOLFIRINOX

Folinic acid, 5-FU, Irinotecan, Oxaliplatin

Trial Locations (2)

48201

RECRUITING

Karmanos Cancer Center, Detroit

77030

RECRUITING

Baylor College of Medicine, Houston

Sponsors

Lead Sponsor

Oncotelic Inc.
All Listed Sponsors
lead

Oncotelic Inc.

INDUSTRY